

DIFAEM-EPN Minilab Network News 2 /2023

November 2023

Dear EPN partners,

Today you receive an extract from the internal newsletter of DIFAEM-EPN Minilab Network. We would like to draw your attention to substandard and falsified medicines, which have recently been identified by the DIFAEM-EPN Minilab Network using the GPHF Minilab. These products are harmful for patients and must not be used. In case you encounter one of these products, immediately remove it from the shelf and quarantine or destroy it according to the procedures of your organization/facility. Please do not return these products to the supplier as in this manner they might be resold to other customers. In case of question you may contact us using the email addresses below.

Have a pleasant reading.

Kind regards,

Christine and Gabi



Christine Haefele-Abah, Pharmacist, MScIH
Head Pharmaceutical Procurement & Projects
E-Mail: haefele@difaem.de




Gabi Gohl, Pharmacist
Pharmaceutical Projects & Procurement
E-Mail: gohl@difaem.de

Tel.: +49 7071 / 206 851 DIFAEM – German Institute for Medical Mission - Im Rotbad 46, D-72076 Tübingen

Richard and Austine



Richard Neci Cizungu,
Executive Director
E-Mail: richard.neci@epnetwork.org



Austine Opiata, Program Officer
Supply Chain and Quality Assurance
E-Mail : aopiata@epnetwork.org



Ecumenical Pharmaceutical Network P.O.Box 749-00606 | Mais 1 | Kirichwa Flats | LR No. 2/68 Kirichwa Road, off Argwings Kodhek road -Kilimani | Nairobi | Kenya Tel: +254 724 301755 | 0703 656 800

Recent confirmed cases of falsified products reported to WHO

Please note that in all cases batches other than those shown may also be affected.


AMOLAV, Amoxicillin/Clavulanic Acid 625 mg

- Stated manufacturer: Fartrich Pharm Pvt, Selaqui, India
- Batch: 220716
- Mfg. Date: 07/2022
- Exp. Date: 06/2025
- Result of compendial analysis by MEDS: Amoxicillin (92,6%), Clavulanic Acid (0,0%)
- Detected in Nigeria in July 2023
- Reported to WHO by Difaem
- Additional information: NAFDAC Reg No : A4-4108 on the label, was not found in the system





Zimilat, Amoxicillin/Clavulanic Acid 625 mg

- Stated manufacturer: NEMEL Pharmaceuticals Limited, Enugu, Nigeria
- Batch: 01E and 021
- Mfg. Date: Batch 01E (05/2023), Batch 021 (09/2022)
- Exp. Date: Batch 01E (04/2025), Batch 021 (08/2024)
- Result of compendial analysis by MEDS: Batch 01E Amoxicillin (66,0%), clavulanic Acid (8,7%)
Batch 021 Amoxicillin (52,7%), clavulanic Acid (0,0%)
- Detected in Nigeria in July 2023
- Reported to WHO by Difaem
- Additional information: NAFDAC Reg No: B4-1592 on the label indicated wrong product



CEFIXIME, Cefixime 400 mg

- Stated manufacturer: MERCK CO.EMC
- Batch: illegible
- Mfg. Date: 01/2021
- Exp. Date: 02/2025
- Result of compendial analysis by MEDS: Cefixime (0,0%)
- Detected in DRC in February 2023
- Reported to WHO by Difaem



CEFIXIME, Cefixime 400 mg

- Stated manufacturer: Apotex Inc, Canada
- Batch: MGJ516
- Mfg. Date: 06/2021
- Exp. Date: 07/2024
- Result of compendial analysis by MEDS: Cefixime (0,0%)
- Detected in DRC in February 2023
- Reported to WHO by Difaem

